EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings

EQRx Inc EQRX, along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-small cell lung cancer (NSCLC).

  • The trial met the key secondary endpoint of prolonging overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapy.
  • These results build on previously presented positive data from the GEMSTONE-302 study, which met the primary endpoint of progression-free survival (PFS) and were recently published in The Lancet Oncology.
  • Related: Corvex, Casdin Backed SPAC To Merge With EQRx In $1.8B Deal.
  • Clinical benefit was observed across subgroups, including patients with squamous and non-squamous subtypes, regardless of PD-L1 expression levels. 
  • As previously reported, the safety profile of sugemalimab was consistent with that of the PD-1/PD-L1 class.
  • Detailed results will be submitted for presentation at a future medical congress.
  • Additionally, the companies are investigating sugemalimab as consolidation therapy in patients with locally advanced, unresectable stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy in Phase 3 GEMSTONE-301 study. 
  • Positive PFS data from GEMSTONE-301 were also presented at ESMO 2021 and recently published in The Lancet Oncology.
  • Price Action: EQRX shares are down 1.91% at $6.16 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsNon-Small Cell Lung CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!